Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 222,148,560
  • Shares Outstanding, K 959,025
  • Annual Sales, $ 24,540 M
  • Annual Income, $ 6,194 M
  • 60-Month Beta 0.25
  • Price/Sales 8.99
  • Price/Cash Flow 29.00
  • Price/Book 37.35
Trade LLY with:

Options Overview

Details
  • Implied Volatility 29.21%
  • Historical Volatility 23.32%
  • IV Percentile 50%
  • IV Rank 35.49%
  • IV High 44.72% on 03/12/21
  • IV Low 20.69% on 06/22/21
  • Put/Call Vol Ratio 1.16
  • Today's Volume 8,383
  • Volume Avg (30-Day) 5,490
  • Put/Call OI Ratio 1.02
  • Today's Open Interest 76,282
  • Open Int (30-Day) 69,784

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate 1.97
  • Number of Estimates 4
  • High Estimate 2.03
  • Low Estimate 1.92
  • Prior Year 1.54
  • Growth Rate Est. (year over year) +27.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
227.29 +1.91%
on 09/20/21
272.91 -15.12%
on 08/23/21
-39.27 (-14.50%)
since 08/20/21
3-Month
217.00 +6.75%
on 06/23/21
275.87 -16.03%
on 08/17/21
+13.09 (+5.99%)
since 06/18/21
52-Week
129.21 +79.27%
on 10/30/20
275.87 -16.03%
on 08/17/21
+77.47 (+50.25%)
since 09/18/20

Most Recent Stories

More News
Merck (MRK) Keytruda Gets CHMP Nod for Severe Breast Cancer

The CHMP recommends an approval of Merck's (MRK) Keytruda combo for the treatment of patients with metastatic triple-negative breast cancer.

RHHBY : 45.5700 (-1.09%)
BMY : 60.50 (-1.32%)
MRK : 71.93 (+0.35%)
LLY : 231.64 (+0.67%)
Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study

Mirati (MRTX) reports positive data from a cohort of the phase I/IIstudy evaluating its KRAS inhibitor adagrasib in patients with KRAS G12C-mutated colorectal cancer.

MRK : 71.93 (+0.35%)
LLY : 231.64 (+0.67%)
AMGN : 215.11 (-1.95%)
MRTX : 177.45 (+1.95%)
Thermo Fisher (TMO) Introduces New Automated Enzyme Analyzers

The two new Gallery Enzyme Master systems by Thermo Fisher (TMO) offer enhanced reliable enzyme analysis across several enterprises.

LLY : 231.64 (+0.67%)
TMO : 590.20 (-1.11%)
IDXX : 659.78 (-0.29%)
SMLR : 107.7500 (-0.89%)
Growth Hormone Deficiency Market: Company Profiles, Growth Strategy, Developing Technologies, Opportunities and Forecast by Regions till 2028

Research Nester published a report titled  which delivers a detailed overview of the growth hormone deficiency market in terms of market segmentation by application, by route of administration, by distribution...

TEVA : 8.69 (-3.34%)
NOVN : 8.25 (-3.62%)
PFE : 44.20 (+0.71%)
LLY : 231.64 (+0.67%)
MRK : 71.93 (+0.35%)
Turner Syndrome Market: by Industry Type, Growth, Share, Size, Key Manufacturers, Revenue, Trends, Growth, Geographical Outlook and Forecast to 2028

Research Nester published a report titled ": Global Demand Analysis & Opportunity Outlook 2028"which delivers a detailed overview of the turner syndrome drug market in terms of market segmentation by type,...

PFE : 44.20 (+0.71%)
NOVN : 8.25 (-3.62%)
BHC : 26.11 (-4.25%)
JNJ : 163.81 (-0.57%)
LLY : 231.64 (+0.67%)
ABT : 124.87 (-1.51%)
MRK : 71.93 (+0.35%)
SAN : 3.40 (-5.03%)
GSK.LN : 1,408.200 (+0.30%)
Lilly (LLY) Gets FDA Nod for Expanded Use of COVID Cocktail

FDA revises Lilly's (LLY) EUA for COVID-19 antibody cocktail, bamlanivimab and etesevimab, for post-exposure prophylaxis for COVID-19.

REGN : 640.89 (-1.69%)
GSK : 38.85 (-0.21%)
LLY : 231.64 (+0.67%)
VIR : 49.70 (-8.87%)
AbbVie (ABBV) Files for Rinvoq in Ulcerative Colitis in US & EU

AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq - active ulcerative colitis.

PFE : 44.20 (+0.71%)
LLY : 231.64 (+0.67%)
INCY : 75.91 (-0.11%)
ABBV : 106.40 (-1.23%)
Pharma Stock Roundup: ABBV's Deal With RGNX, LLY COVID Drug's Government Order Win

AbbVie (ABBV) buys rights to Regenexbio's gene therapy candidate for chronic retinal diseases. Lilly (LLY) will supply additional doses of its COVID-19 antibody medicine to the U.S. government.

MRK : 71.93 (+0.35%)
LLY : 231.64 (+0.67%)
ABBV : 106.40 (-1.23%)
TBPH : 6.88 (-3.23%)
AERI : 11.59 (-10.43%)
RGNX : 43.58 (-3.24%)
Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19

/PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure...

LLY : 231.64 (+0.67%)
Regeneron, Lilly Get New COVID Drug Deals From Government

Regeneron (REGN) is set to supply an additional 1.4 million doses of its antibody cocktail for COVID-19, REGEN-COV while Lilly (LLY) will supply 388,000 doses of its COVID-19 antibody medicine, etesevimab...

REGN : 640.89 (-1.69%)
GSK : 38.85 (-0.21%)
RHHBY : 45.5700 (-1.09%)
LLY : 231.64 (+0.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

3rd Resistance Point 239.26
2nd Resistance Point 235.99
1st Resistance Point 233.82
Last Price 231.64
1st Support Level 228.38
2nd Support Level 225.11
3rd Support Level 222.94

See More

52-Week High 275.87
Last Price 231.64
Fibonacci 61.8% 219.85
Fibonacci 50% 202.54
Fibonacci 38.2% 185.23
52-Week Low 129.21

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar